Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on May 31, 2024.

Summary

• Lilly Endowment Inc. sold 20,806 shares of Eli Lilly & Co. common stock at a weighted average price of $822.04 on May 31, 2024.
• These shares were sold in multiple transactions with prices ranging from $822.00 to $822.7975.
• Additionally, Lilly Endowment Inc. sold 1,400 shares of Eli Lilly & Co. common stock at a weighted average price of $823.219 on the same day.
• These shares were sold in multiple transactions with prices ranging from $823.04 to $823.33.
• Following these transactions, Lilly Endowment Inc. beneficially owns 98,401,604 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a routine filing of a share sale, with no indication of positive or negative sentiment.

Industry Context

This filing reflects a routine transaction by a major shareholder and is not indicative of any specific industry trend or competitive shift.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies.
• The transaction is similar to other large institutional investors adjusting their positions in response to market conditions or portfolio rebalancing strategies.
• The sale of 22,206 shares is a relatively small percentage of Lilly Endowment Inc.'s total holdings of 98,401,604 shares.

Stakeholder Impact

• The sale of shares by Lilly Endowment Inc. may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, LLY